MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: NEC Corporation
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Aichi Cancer Center and NEC Launch Joint Research on Fundamental Study Aimed At Advanced Cancer Immunotherapy through the Fusion of AI And Experimenta - Aichi Cancer Center and NEC launch joint research on fundamental study aimed at advanced cancer immunotherapy through the fusion of AI and experimental immunology - pref.Aichi.jp / NEC.com
Aichi Cancer Center and NEC Launch Joint Research on Fundamental Study Aimed At Advanced Cancer Immunotherapy through the Fusion of AI And Experimenta

 

NewswireToday - /newswire/ - Nagoya, Japan, 2020/07/06 - Aichi Cancer Center and NEC launch joint research on fundamental study aimed at advanced cancer immunotherapy through the fusion of AI and experimental immunology - pref.Aichi.jp / NEC.com. NEC; TSE: 6701

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Engineering / Artificial Intelligence Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Aichi Cancer Center (*1) and NEC Corporation today announced the launch of fundamental research aiming to realize the promise of advanced personalized cancer immunotherapy by improving the performance of NEC’s neoantigen prediction system and developing predictive biomarkers for patient stratification through the fusion of AI and experimental immunology.

This research aims to identify suitable neoantigen for vaccine use by using the neoantigen prediction system which NEC has been working on and the screening techniques using T cells for neoantigen from Aichi Cancer Center. In addition, this research aims to develop biomarkers for patient stratification using AI based on analytical data on a tumor immune microenvironment and clinical data.

The partners will realize the promise of advanced personalized cancer immunotherapy which boosts the immune system especially in combination with immune checkpoint inhibitors (ICIs).

Background

Although the ICIs showed a certain degree of therapeutic success in cancer therapeutics, the therapeutic effect is limited to few cases. Previous studies have suggested that there is a significant correlation between tumor neoantigen load and the clinical efficacy of ICIs. Accordingly, the immunotherapy could improve the therapeutic efficacy if the brakes on the immune system are disabled, and at the same time, the immune responses to neoantigens are accelerated. The important things for realizing effective cancer immunotherapies are 1.) the selection of neoantigens that harness the immune system and 2.) the patient stratification in treatment planning for ICI therapy, cancer vaccine therapy, and their combination therapy.

The Division of Translational Oncoimmunology at the Aichi Cancer Center has been conducting translational research using patient samples in collaboration with the departments of Thoracic Surgery and Thoracic Oncology at the Aichi Cancer Center Hospital (pref.aichi.jp). Specifically, this division specializes in experimental immunology and focuses on analyzing the immune microenvironment and the tumor-specific immune responses of each patient.

NEC (nec.com) is actively working on applied research in the drug development field using AI and has developed a unique AI-based neoantigen prediction system. NEC was accepted into the Tumor neoantigEn SeLection Alliance (TESLA) consortium given the uniqueness of this system and became the first Japanese company to join TESLA, founded and managed by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute. (*2)

Outline of the Joint Research

1. Performance improvement of the neoantigen prediction system
Aichi Cancer Center and NEC will identify neoantigens recognized by T cells by using both the neoantigen prediction system and the immunological experimental approach. In the future, NEC will improve the performance of the neoantigen prediction system by using this high-quality data.

2. Development of biomarkers for patient stratification
Aichi Cancer Center and NEC will comprehensively analyze the tumor immune microenvironment of each patient. This research aims to develop biomarkers for patient stratification using AI based on clinical information, genetic mutation, gene expression, and experimental data obtained from experiments described above.

Future Initiatives

Aichi Cancer Center will aim to carry out clinical trials of cancer immunotherapy. The clinical trials of cancer immunotherapy will be conducted at Aichi Cancer Center Hospital, and additional research will be conducted at Aichi Cancer Center Research Institute. The hospital and research institute will work together as a comprehensive cancer center.

NEC has been conducting applied research in the drug development field using AI for about 20 years. Through this joint research, NEC will accelerate its AI-driven drug development business by improving the performance of neoantigen prediction systems and developing biomarkers for patient stratification.

Notes

*1)Aichi Cancer Center
Designated by Japan's Minister of Health, Labour and Welfare as a hub hospital for cancer genome medical care.
*2)NEC becomes the first Japanese company to join the TESLA consortium's fight against cancer

About NEC Corporation

NEC Corporation (nec.com) has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential.

NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners. ©2020 NEC Corporation.

Technical Contacts:
Aichi Cancer Center - Division of Translational Oncoimmunology
E: h.matsushita[.]aichi-cc.jp

NEC Corporation - AI Drug Development Division
E: contact[.]aidd.jp.nec.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Engineering / Artificial Intelligence Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: NEC Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Engineering / Artificial Intelligence articles,
CATCH Visitors via Your Competitors Announcements!


Aichi Cancer Center and NEC Launch Joint Research on Fundamental Study Aimed At Advanced Cancer Immunotherapy through the Fusion of AI And Experimenta

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NEC Corporation securities in any jurisdiction including any other companies listed or named in this release.

Engineering / Artificial Intelligence via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From NEC Corporation / Company Profile


Read Engineering / Artificial Intelligence Most Recent Related Newswires:

ABB’s New Analytics and AI Software Helps Producers Optimize Operations in Demanding Market Conditions
NEC and Realeyes Announce Strategic Alliance in Emotion Analysis Solutions
BASF and IntelliSense.io Partner to Accelerate the Mining Industry’s Digital Transformation
BASF Invests in Technology Company SmartAHC - A Specialist in Artificial Intelligence for Animal Husbandry
ABB Adds Accenture as Digital Development Partner
Qualcomm Brings Advanced Artificial Intelligence and Machine Learning Capabilities to Address Multiple Tiers of Smart Cameras with New System-on-Chips
Percepto Mitigates COVID-19 Impact with Autonomous Drone Technology
Kantar Launches Fully AI-powered Creative Effectiveness Measurement Tool
Kontron Certified as a 'Preferred Partner' Under the NVIDIA Partner Program and Uses NVIDIA's Powerful Graphics Performance Units
The Thales AI@Centech Program Accelerates the Success of the World’s Most Promising AI Innovators
Global Airlines Leverage AI, Machine Learning and Blockchain to Save Costs and Generate New Revenues Says Frost & Sullivan
Siemens Extends Xcelerator Portfolio to Help Transform Electrical/electronic Systems Development
Qualcomm Launches World’s First 5G and AI-Enabled Robotics Platform
SAS and Microsoft Partner to Further Shape the Future of Analytics and AI
Atos Public Safety, LLC Awarded by Frost & Sullivan for Driving the Growth of Next Generation 9-1-1 in the U.S

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow, Inc.





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)